231 related articles for article (PubMed ID: 16407256)
21. Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is inhibited by Cdk5 activators and does not contribute to the activation of Cdk5.
Kobayashi H; Saito T; Sato K; Furusawa K; Hosokawa T; Tsutsumi K; Asada A; Kamada S; Ohshima T; Hisanaga S
J Biol Chem; 2014 Jul; 289(28):19627-36. PubMed ID: 24872417
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins.
Zhou J; Wang H; Feng Y; Chen J
Life Sci; 2010 Mar; 86(13-14):532-7. PubMed ID: 20153752
[TBL] [Abstract][Full Text] [Related]
23. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity.
Tomizawa K; Ohta J; Matsushita M; Moriwaki A; Li ST; Takei K; Matsui H
J Neurosci; 2002 Apr; 22(7):2590-7. PubMed ID: 11923424
[TBL] [Abstract][Full Text] [Related]
24. Kinetic mechanism of activation of the Cdk2/cyclin A complex. Key role of the C-lobe of the Cdk.
Morris MC; Gondeau C; Tainer JA; Divita G
J Biol Chem; 2002 Jun; 277(26):23847-53. PubMed ID: 11959850
[TBL] [Abstract][Full Text] [Related]
25. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism.
Clare PM; Poorman RA; Kelley LC; Watenpaugh KD; Bannow CA; Leach KL
J Biol Chem; 2001 Dec; 276(51):48292-9. PubMed ID: 11604388
[TBL] [Abstract][Full Text] [Related]
26. Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation.
Sharma P; Sharma M; Amin ND; Albers RW; Pant HC
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11156-60. PubMed ID: 10500146
[TBL] [Abstract][Full Text] [Related]
27. Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.
Zhang B; Tan VB; Lim KM; Tay TE; Zhuang S
J Mol Model; 2007 Jan; 13(1):79-89. PubMed ID: 16770643
[TBL] [Abstract][Full Text] [Related]
28. Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity.
Habran L; Bontems S; Di Valentin E; Sadzot-Delvaux C; Piette J
J Biol Chem; 2005 Aug; 280(32):29135-43. PubMed ID: 15955820
[TBL] [Abstract][Full Text] [Related]
29. Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Brain Res Mol Brain Res; 2002 Oct; 106(1-2):50-6. PubMed ID: 12393264
[TBL] [Abstract][Full Text] [Related]
30. The role of CDK5/P25 formation/inhibition in neurodegeneration.
Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
[TBL] [Abstract][Full Text] [Related]
31. Specific Conformational Dynamics and Expansion Underpin a Multi-Step Mechanism for Specific Binding of p27 with Cdk2/Cyclin A.
Tsytlonok M; Hemmen K; Hamilton G; Kolimi N; Felekyan S; Seidel CAM; Tompa P; Sanabria H
J Mol Biol; 2020 Apr; 432(9):2998-3017. PubMed ID: 32088186
[TBL] [Abstract][Full Text] [Related]
32. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.
Schmid G; Strosznajder JB; Wesierska-Gadek J
Mol Neurobiol; 2006 Aug; 34(1):27-50. PubMed ID: 17003520
[TBL] [Abstract][Full Text] [Related]
33. Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors.
Liu M; Choi S; Cuny GD; Ding K; Dobson BC; Glicksman MA; Auerbach K; Stein RL
Biochemistry; 2008 Aug; 47(32):8367-77. PubMed ID: 18636751
[TBL] [Abstract][Full Text] [Related]
34. Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5.
Goodyear S; Sharma MC
Exp Mol Pathol; 2007 Feb; 82(1):25-32. PubMed ID: 17081516
[TBL] [Abstract][Full Text] [Related]
35. Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors.
Ul Haq Z; Uddin R; Wai LK; Wadood A; Lajis NH
J Mol Model; 2011 May; 17(5):1149-61. PubMed ID: 20686908
[TBL] [Abstract][Full Text] [Related]
36. Intrathecal administration of roscovitine prevents remifentanil-induced postoperative hyperalgesia and decreases the phosphorylation of N-methyl-D-aspartate receptor and metabotropic glutamate receptor 5 in spinal cord.
Liu X; Liu Y; Zhang J; Zhang W; Sun YE; Gu X; Ma Z
Brain Res Bull; 2014 Jul; 106():9-16. PubMed ID: 24769228
[TBL] [Abstract][Full Text] [Related]
37. The cyclin-dependent kinase inhibitor roscovitine inhibits kinase activity, cell proliferation, multicellular development, and Cdk5 nuclear translocation in Dictyostelium discoideum.
Huber RJ; O'Day DH
J Cell Biochem; 2012 Mar; 113(3):868-76. PubMed ID: 22234985
[TBL] [Abstract][Full Text] [Related]
38. Conformational Equilibrium of CDK/Cyclin Complexes by Molecular Dynamics with Excited Normal Modes.
Floquet N; Costa MG; Batista PR; Renault P; Bisch PM; Raussin F; Martinez J; Morris MC; Perahia D
Biophys J; 2015 Sep; 109(6):1179-89. PubMed ID: 26255588
[TBL] [Abstract][Full Text] [Related]
39. Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex.
De Vivo M; Cavalli A; Bottegoni G; Carloni P; Recanatini M
Proteins; 2006 Jan; 62(1):89-98. PubMed ID: 16292742
[TBL] [Abstract][Full Text] [Related]
40. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.
Patrick GN; Zhou P; Kwon YT; Howley PM; Tsai LH
J Biol Chem; 1998 Sep; 273(37):24057-64. PubMed ID: 9727024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
